Native Antigen

Founded in 2010, The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease reagents.

Their portfolio of reagents continues to expand, and they are widely acknowledged to be a primary source of reagents and kits for the study of emerging diseases. In July of 2020, The Native Antigen Company was acquired by The LGC Group, a global leader in the life sciences sector, and is now part of the LGC Clinical Diagnostics business unit.

We were tasked to deliver The Native Antigen company’s new HQ & R&D facility at the Oxford Technology Park over two storeys. The works involved compliant (CL2) laboratories created within warehouse space on the ground floor and associated offices on the first floor.

Bulb secured as a tendered project, the delivery of a 30,000 sq. ft. interior fit-out of their new R&D facility, as initially designed by Rapleys’s LLP as the Principal Designer. The Oxford Technology Park is a brand-new park in North Oxford (still under construction).

On the ground floor, we delivered a reception, various life sciences laboratories such as tissue culture, purification, microbiology, wet chemistry with support rooms including a cold room, a dark room, glass wash, material storage and a dispatch area.

Laboratory services included a ventilation strategy, small & resilient power provision, specialist lighting, vulcathene drainage and industrial gases distribution.

A separate suite was created to carry out genomics work by another portfolio company of The LGC Group.

The first floor was comprised of a modern open office and a selection of cellular offices, meeting rooms, well-being room and a spacious breakout area with ability to expand in future.